No connection

Search Results

ETON

BEARISH
$26.39 Live
Eton Pharmaceuticals, Inc. · NASDAQ
Target $39.33 (+49.0%)
$11.38 52W Range $26.81

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 09, 2026
Market cap
$720.17M
P/E
N/A
ROE
-18.2%
Profit margin
-5.8%
Debt/Equity
1.19
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
75%
ETON shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 2/9). Concerns include weak profitability or high valuation.

Key Strengths

Strong revenue growth of 82.7%

Key Risks

Low profit margin of -5.8%
Weak financial trend (Piotroski F-Score: 2/9)
Weak ROE of -18.2%

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
35
Weak
Value
50
Future
65
Past
30
Health
30
Dividend
0
AI Verdict
ETON shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 2/9). Concerns include weak profitability or high valuation.
Key drivers: Strong revenue growth of 82.7%, Low profit margin of -5.8%, Weak financial trend (Piotroski F-Score: 2/9)
Confidence
35%
Value
50/100

Rule-based valuation (P/E + Graham).

Positives
  • Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Future
65/100

Rule-based growth outlook.

Positives
  • Revenue growth running at 82.7%.
Watchpoints
No urgent risks highlighted.
Past
30/100

Historical performance + price trend: Shares moved +251.9% over 5Y and +130.1% over 1Y.

Positives
  • Insufficient data for clear positives.
Watchpoints
  • ROE only -18.2%.
  • Thin profit margins.
Health
30/100

Balance sheet & liquidity (Z-Score: N/A).

Positives
  • Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Dividend
0/100

Dividend policy fallback.

Positives
  • Insufficient data for clear positives.
Watchpoints
  • No regular dividend payments.

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$26.39
Analyst Target
$39.33
Upside/Downside
+49.0%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for ETON and closest competitors.

Updated 2026-04-08
ETO
Eton Pharmaceuticals, Inc.
Primary
5Y
+251.9%
3Y
+598.3%
1Y
+130.1%
6M
+26.1%
1M
+58.0%
1W
+4.1%
BBN
Beta Bionics, Inc.
Peer
5Y
-32.5%
3Y
-32.5%
1Y
-32.5%
6M
+7.5%
1M
-48.7%
1W
-13.7%
BGM
BGM Group Ltd.
Peer
5Y
-90.8%
3Y
-38.2%
1Y
-66.0%
6M
-64.4%
1M
-12.5%
1W
0.0%
ARV
Arvinas, Inc.
Peer
5Y
-84.3%
3Y
-57.8%
1Y
+42.5%
6M
+57.4%
1M
-7.0%
1W
-10.4%
AMN
AMN Healthcare Services, Inc.
Peer
5Y
-72.8%
3Y
-78.8%
1Y
-26.3%
6M
+3.5%
1M
+28.0%
1W
+7.7%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
16.92
PEG Ratio
N/A
P/B Ratio
27.3
P/S Ratio
9.01
EV/Revenue
9.08
EV/EBITDA
81.8
Market Cap
$720.17M

Profitability

Profit margins and return metrics

Profit Margin -5.75%
Operating Margin 20.99%
Gross Margin 59.83%
ROE -18.19%
ROA 3.59%

Growth

Revenue and earnings growth rates

Revenue Growth +82.7%
Earnings Growth N/A
Q/Q Revenue Growth +82.72%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
1.19
Moderate
Current Ratio
1.57
Good
Quick Ratio
0.98
Poor
Cash/Share
$0.95

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
61.6%
Op. Margin
11.6%
Net Margin
7.0%
Total Assets
$0.1B
Liabilities
$0.1B
Equity
$0.0B
Debt/Equity
2.52x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-12
$N/A
2026-03-19
$0.19
-5.0% surprise
2025-11-06
$0.04
-75.0% surprise
2025-08-07
$0.03
+28.6% surprise

Healthcare Sector Comparison

Comparing ETON against 189 companies in the Healthcare sector (17 bullish, 63 neutral, 109 bearish)
Return on Equity (ROE)
-18.19%
This Stock
vs
-44.08%
Sector Avg
-58.7% (Below Avg)
Profit Margin
-5.75%
This Stock
vs
-19.57%
Sector Avg
-70.6% (Weaker)
Debt to Equity
1.19
This Stock
vs
5.1
Sector Avg
-76.7% (Less Debt)
Revenue Growth
82.7%
This Stock
vs
108.17%
Sector Avg
-23.5% (Slower)
Current Ratio
1.57
This Stock
vs
3.39
Sector Avg
-53.6% (Weaker)

Similar Companies

Peer comparison within the same industry

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

RIEDEL NORBERT G
Director
Option Exercise
2026-02-03
30,000 shares · $132,600
Insider transactions can signal confidence or concerns about company prospects

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
NONE
3 analysts
B. Riley Securities
2026-03-20
Maintains
Buy Buy
HC Wainwright & Co.
2026-03-20
Maintains
Buy Buy
Craig-Hallum
2026-03-20
Maintains
Buy Buy
Craig-Hallum
2026-03-03
Maintains
Buy Buy
HC Wainwright & Co.
2026-03-02
Maintains
Buy Buy

Past News Coverage

Recent headlines mentioning ETON from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile